{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:40Z","timestamp":1792787260158,"version":"4.5.0"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Center for Drug Evaluation and Research at the US FDA","award":["75F40120C0044"],"award-info":[{"award-number":["75F40120C0044"]}],"id":[{"id":"https:\/\/ror.org\/00yf3tm42","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clozapine is highly effective for treatment-resistant schizophrenia but has been associated with an increased risk of agranulocytosis. As a result, until 2025, the Food and Drug Administration required patients receiving clozapine to undergo regular blood testing to monitor for neutropenia as part of a Risk Evaluation and Mitigation Strategy (REMS) programme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study sought to compare the risk of neutropenia-related hospitalisations between clozapine and olanzapine initiators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study cohort was nested in claims data from Medicaid and two commercial health insurance databases and consisted of adults initiating clozapine or olanzapine who had a recorded diagnosis of schizophrenia or schizoaffective disorder and \u22651 dispensing of a different antipsychotic in the 6 months before initiation. Propensity score matching (1:1) was used to mitigate confounding. The primary outcome was hospitalisation with a neutropenia diagnosis in the primary position. Both as-treated and intention-to-treat analyses were implemented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>After propensity score matching, there were 16\u2009873 initiators in each group. At 6 months postinitiation, there were 12 neutropenia-related hospitalisations among the clozapine cohort (incidence rate: 2.21 per 1000 person-years; 95% CI 1.25 to 3.89) and &lt;11 among the olanzapine cohort (0.18; 95%\u2009CI 0.03 to 1.29), corresponding to an incidence rate ratio (IRR) of 12.18 (95% CI 1.58 to 93.71). The IRRs were 5.77 (95% CI 1.29 to 25.76) at 1 year, 5.50 (95% CI 1.23 to 24.55) at 2 years and 5.40 (95% CI 1.21 to 24.13) at 3 years postinitiation. Associations remained but were attenuated in intention-to-treat analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clozapine initiators had an elevated risk of neutropenia-related hospitalisation, especially during the first 6 months of treatment, although the absolute risk was low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>Despite removal of the REMS programme, it is important for prescribers to monitor patients for neutropenia after initiating clozapine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2025-302122","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T13:22:52Z","timestamp":1770384172000},"page":"e302122","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of neutropenia-related hospitalisation among clozapine initiators"],"prefix":"10.1136","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5043-6206","authenticated-orcid":false,"given":"Ameet","family":"Sarpatwari","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mufaddal","family":"Mahesri","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Lii","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Been","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Zakoul","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita A","family":"Toyserkani","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther H","family":"Zhou","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Lacivita","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J","family":"Dal Pan","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3336-5412","authenticated-orcid":false,"given":"Katsiaryna","family":"Bykov","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Moran","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Avorn","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista F","family":"Huybrechts","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"2026091806101796000_29.1.e302122.1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"2026091806101796000_29.1.e302122.2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia","volume":"60","author":"Meltzer","year":"2003","journal-title":"International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry"},{"key":"2026091806101796000_29.1.e302122.3","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.115.177261"},{"key":"2026091806101796000_29.1.e302122.4","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12742"},{"key":"2026091806101796000_29.1.e302122.5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300180"},{"key":"2026091806101796000_29.1.e302122.6","article-title":"History of Suicide Attempt and Clozapine Treatment in Veterans With Schizophrenia or Schizoaffective Disorder","volume":"24","author":"Jones","year":"2022","journal-title":"Prim Care Companion CNS Disord"},{"key":"2026091806101796000_29.1.e302122.7","unstructured":"US Food and Drug Administration . CLOZARIL-clozapine tablet. 2025. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=5f0c6f5f-b906-4c8f-8580-3939a476a1c1"},{"key":"2026091806101796000_29.1.e302122.8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(75)90206-8","article-title":"Letter: Clozapine and agranulocytosis","volume":"2","author":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1975","journal-title":"Lancet"},{"key":"2026091806101796000_29.1.e302122.9","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442576"},{"key":"2026091806101796000_29.1.e302122.10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.9740\/mhc.2018.03.063","article-title":"Assessing prescribing practices of clozapine before and after the implementation of an updated risk evaluation and mitigation strategy","volume":"8","author":"Curry","year":"2018","journal-title":"Ment Health Clin"},{"key":"2026091806101796000_29.1.e302122.11","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1056\/NEJMp1803910","article-title":"The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later","volume":"379","author":"Avorn","year":"2018","journal-title":"N Engl J Med"},{"key":"2026091806101796000_29.1.e302122.12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.59311","article-title":"Physician Experiences With and Perspectives on Clozapine Prescribing","volume":"8","author":"Sarpatwari","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026091806101796000_29.1.e302122.13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JCP.0000000000001606","article-title":"The Modernization of Clozapine: A Recapitulation of the Past in the United States and the View Forward","volume":"42","author":"Leung","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"2026091806101796000_29.1.e302122.14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2215-0366(23)00343-7","article-title":"Evaluating the epidemiology of clozapine-associated neutropenia among people on clozapine across Australia and Aotearoa New Zealand: a retrospective cohort study","volume":"11","author":"Northwood","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"2026091806101796000_29.1.e302122.15","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.2147\/NDT.S209284","article-title":"A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future","volume":"15","author":"Citrome","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2026091806101796000_29.1.e302122.16","unstructured":"FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug clozapine. US Food and Drug Administration. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-removes-risk-evaluation-and-mitigation-strategy-rems-program-antipsychotic-drug-clozapine?utm_medium=email&utm_source=govdelivery [Accessed 27 Aug 2025]."},{"key":"2026091806101796000_29.1.e302122.17","unstructured":"FDA briefing document: risk evaluation and mitigation strategy (REMS) for clozapine products. US Food and Drug Administration; 2024. Available: https:\/\/www.fda.gov\/media\/183546\/download [Accessed 1 Dec 2025]."},{"key":"2026091806101796000_29.1.e302122.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.10.004"},{"key":"2026091806101796000_29.1.e302122.19","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000824"},{"key":"2026091806101796000_29.1.e302122.20","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"2026091806101796000_29.1.e302122.21","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6058"},{"key":"2026091806101796000_29.1.e302122.22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S2215-0366(24)00097-X","article-title":"Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland","volume":"11","author":"Rubio","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"2026091806101796000_29.1.e302122.23","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212272","article-title":"Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function","volume":"4","author":"Blanchette","year":"2015","journal-title":"Drugs Context"},{"key":"2026091806101796000_29.1.e302122.24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40264-024-01443-3","article-title":"Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000-2020","volume":"47","author":"Mahesri","year":"2024","journal-title":"Drug Saf"},{"key":"2026091806101796000_29.1.e302122.25","unstructured":"US Food and Drug Administration . Information on clozapine. 2025. Available: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/information-clozapine [Accessed 30 Oct 2025]."},{"key":"2026091806101796000_29.1.e302122.26","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2183192"},{"key":"2026091806101796000_29.1.e302122.27","unstructured":"Frysh P . Schizophrenia: is the fda hindering the most effective med? WebMD. 2023. Available: https:\/\/www.webmd.com\/schizophrenia\/features\/schizophrenia-fda-hindering-clozapine [Accessed 30 Oct 2025]."},{"key":"2026091806101796000_29.1.e302122.28","unstructured":"Berry E , F.D.A . Expands access to clozapine, a key treatment for schizophrenia. New York Times; 2025. Available: https:\/\/www.nytimes.com\/2025\/02\/25\/health\/clozapine-schizophrenia-fda.html [Accessed 25 Feb 2025]."}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2025-302122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:10:37Z","timestamp":1789737037000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2025-302122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,6]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjment-2025-302122"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2025-302122","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}